AC Immune Net Worth
AC Immune Net Worth Breakdown | ACIU |
AC Immune Net Worth Analysis
AC Immune's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AC Immune's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AC Immune's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AC Immune's net worth analysis. One common approach is to calculate AC Immune's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AC Immune's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AC Immune's net worth. This approach calculates the present value of AC Immune's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AC Immune's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AC Immune's net worth. This involves comparing AC Immune's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AC Immune's net worth relative to its peers.
Enterprise Value |
|
To determine if AC Immune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AC Immune's net worth research are outlined below:
| AC Immune generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 14.8 M. Net Loss for the year was (54.23 M) with loss before overhead, payroll, taxes, and interest of (20.46 M). | |
| AC Immune currently holds about 154.15 M in cash with (60.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83. | |
| AC Immune has a poor financial position based on the latest SEC disclosures | |
| Roughly 38.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: AC Immune Leader In Dementia Therapies, A Space Littered With Failures - Seeking Alpha |
AC Immune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AC Immune. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AC Immune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 26th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know AC Immune's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AC Immune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AC Immune backward and forwards among themselves. AC Immune's institutional investor refers to the entity that pools money to purchase AC Immune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Millennium Management Llc | 2024-12-31 | 119 K | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 66.3 K | |
| Geode Capital Management, Llc | 2024-12-31 | 64.1 K | |
| Ubs Group Ag | 2024-12-31 | 49.7 K | |
| Squarepoint Ops Llc | 2024-12-31 | 43.8 K | |
| Two Sigma Investments Llc | 2024-12-31 | 40.8 K | |
| Jane Street Group Llc | 2024-12-31 | 24.3 K | |
| China Universal Asset Mgmt Co.ltd | 2024-12-31 | 21 K | |
| Rpo Llc | 2024-12-31 | 18.7 K | |
| Bvf Inc | 2024-12-31 | 19.5 M | |
| Blackrock Inc | 2024-12-31 | 2.2 M |
Follow AC Immune's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 251.32 M.Market Cap |
|
Project AC Immune's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.45) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.30) | (0.32) |
When accessing AC Immune's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AC Immune's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AC Immune's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in AC Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AC Immune. Check AC Immune's Beneish M Score to see the likelihood of AC Immune's management manipulating its earnings.
Evaluate AC Immune's management efficiency
AC Immune has return on total asset (ROA) of (0.1204) % which means that it has lost $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3116) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.45 in 2025. Return On Capital Employed is likely to drop to -0.3 in 2025. Total Current Liabilities is likely to drop to about 12.8 M in 2025. Liabilities And Stockholders Equity is likely to drop to about 193.9 M in 2025| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.71 | 1.70 | |
| Tangible Book Value Per Share | 1.17 | 1.57 | |
| Enterprise Value Over EBITDA | (6.24) | (6.55) | |
| Price Book Value Ratio | 2.55 | 2.42 | |
| Enterprise Value Multiple | (6.24) | (6.55) | |
| Price Fair Value | 2.55 | 2.42 | |
| Enterprise Value | 323.2 M | 498.1 M |
The operational strategies employed by AC Immune management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 1.7425 | Revenue | Quarterly Revenue Growth 14.8 K | Revenue Per Share | Return On Equity |
AC Immune Corporate Filings
6K | 18th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 13th of December 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 26th of July 2024 Other Reports | ViewVerify |
AC Immune Earnings per Share Projection vs Actual
AC Immune Corporate Management
| Julian Snow | VP Development | Profile | |
| Nuno MD | Chief Officer | Profile | |
| Christopher Roberts | Interim Fin | Profile | |
| Sonia Poli | Head Science | Profile | |
| Piergiorgio Donati | Chief Officer | Profile | |
| Pr MD | Chief Officer | Profile | |
| Joshua Drumm | Head Relations | Profile |
Already Invested in AC Immune?
The danger of trading AC Immune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AC Immune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AC Immune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AC Immune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.